PL1725569T3 - Proleki środków antywirusowych na bazie piperazyny i podstawionej piperydyny - Google Patents
Proleki środków antywirusowych na bazie piperazyny i podstawionej piperydynyInfo
- Publication number
- PL1725569T3 PL1725569T3 PL05724510T PL05724510T PL1725569T3 PL 1725569 T3 PL1725569 T3 PL 1725569T3 PL 05724510 T PL05724510 T PL 05724510T PL 05724510 T PL05724510 T PL 05724510T PL 1725569 T3 PL1725569 T3 PL 1725569T3
- Authority
- PL
- Poland
- Prior art keywords
- prodrugs
- piperazine
- antiviral agents
- substituted piperidine
- piperidine antiviral
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- 239000003443 antiviral agent Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55332004P | 2004-03-15 | 2004-03-15 | |
| US63523104P | 2004-12-10 | 2004-12-10 | |
| EP05724510A EP1725569B1 (en) | 2004-03-15 | 2005-03-03 | Prodrugs of piperazine and substituted piperidine antiviral agents |
| PCT/US2005/006980 WO2005090367A1 (en) | 2004-03-15 | 2005-03-03 | Prodrugs of piperazine and substituted piperidine antiviral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1725569T3 true PL1725569T3 (pl) | 2008-09-30 |
Family
ID=34963934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05724510T PL1725569T3 (pl) | 2004-03-15 | 2005-03-03 | Proleki środków antywirusowych na bazie piperazyny i podstawionej piperydyny |
Country Status (26)
| Country | Link |
|---|---|
| US (12) | US7745625B2 (pl) |
| EP (1) | EP1725569B1 (pl) |
| JP (1) | JP4734318B2 (pl) |
| KR (1) | KR101153594B1 (pl) |
| CN (1) | CN101941990B (pl) |
| AR (1) | AR048039A1 (pl) |
| AT (1) | ATE384728T1 (pl) |
| AU (1) | AU2005223736C1 (pl) |
| BR (1) | BRPI0508876B8 (pl) |
| CA (1) | CA2560253C (pl) |
| CY (1) | CY1107419T1 (pl) |
| DE (1) | DE602005004517T2 (pl) |
| DK (1) | DK1725569T3 (pl) |
| ES (1) | ES2299022T3 (pl) |
| GE (1) | GEP20094736B (pl) |
| HR (1) | HRP20080064T5 (pl) |
| IL (1) | IL211961A (pl) |
| MY (1) | MY139243A (pl) |
| NO (1) | NO336742B1 (pl) |
| NZ (2) | NZ585294A (pl) |
| PE (1) | PE20051151A1 (pl) |
| PL (1) | PL1725569T3 (pl) |
| PT (1) | PT1725569E (pl) |
| RS (1) | RS50567B (pl) |
| TW (1) | TWI344843B (pl) |
| WO (1) | WO2005090367A1 (pl) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| US20050075364A1 (en) * | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| CN102358738A (zh) * | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US7130185B2 (en) * | 2004-06-02 | 2006-10-31 | Research In Motion Limited | Handheld computing device having drop-resistant LCD display |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| JP4801096B2 (ja) * | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| US7723338B2 (en) * | 2005-01-31 | 2010-05-25 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine |
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| US7396830B2 (en) | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7501419B2 (en) * | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7572810B2 (en) * | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| US7504399B2 (en) * | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| ES2389478T3 (es) * | 2008-06-25 | 2012-10-26 | Bristol-Myers Squibb Company | Derivados de dicetopiperidina como inhibidores de la fijación del VIH |
| US7960406B2 (en) | 2008-06-25 | 2011-06-14 | Bristol-Myers Squibb Company | Diketo substituted pyrrolo[2,3-c] pyridines |
| EP2323633B1 (en) * | 2008-09-04 | 2012-03-21 | Bristol-Myers Squibb Company | Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
| US8399513B2 (en) * | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| WO2010047775A2 (en) * | 2008-10-20 | 2010-04-29 | Xenoport, Inc. | Methods of synthesizing a levodopa ester prodrug |
| CA2937222C (en) * | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| WO2011056240A2 (en) * | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| BR112012030818A2 (pt) | 2010-06-04 | 2019-09-24 | Bristol-Myers Squibb Company | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" |
| WO2011153319A1 (en) | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| EP2601174B1 (en) | 2010-08-06 | 2014-11-26 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
| HRP20151212T1 (hr) | 2011-01-31 | 2015-12-04 | Bristol-Myers Squibb Company | C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P |
| JP6001560B2 (ja) | 2011-01-31 | 2016-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hiv成熟阻害活性を有するc−17およびc−3修飾トリテルペノイド |
| CN103339130B (zh) | 2011-01-31 | 2015-05-06 | 百时美施贵宝公司 | 制备hiv附着抑制剂前药化合物的方法及中间体 |
| ES2636312T3 (es) | 2011-04-12 | 2017-10-05 | VIIV Healthcare UK (No.5) Limited | Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH |
| WO2013033061A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| CA2849475A1 (en) | 2011-09-21 | 2013-03-28 | Bristol-Myers Squibb Company | Novel betulinic acid derivatives with antiviral activity |
| WO2013078118A1 (en) | 2011-11-21 | 2013-05-30 | Bristol-Myers Squibb Company | Methods for determining the susceptibility of a virus to an attachment inhibitor |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US9248139B2 (en) | 2011-12-21 | 2016-02-02 | Bristol-Myers Squibb Company | Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients |
| MX352320B (es) * | 2012-02-08 | 2017-11-21 | Viiv Healthcare Uk No 4 Ltd | Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana. |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| WO2013138436A1 (en) | 2012-03-14 | 2013-09-19 | Bristol-Myers Squibb Company | Cyclolic hydrazine derivatives as hiv attachment inhibitors |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| SMT201900411T1 (it) | 2012-06-19 | 2019-09-09 | Debiopharm Int Sa | Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide |
| US9505752B2 (en) | 2012-08-09 | 2016-11-29 | Viiv Healthcare Uk (No. 5) Limited | Piperidine amide derivatives as HIV attachment inhibitors |
| EP2895472B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
| EA027371B1 (ru) | 2013-02-06 | 2017-07-31 | Бристол-Майерс Сквибб Компани | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич |
| JP6186012B2 (ja) | 2013-02-25 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C−3アルキルおよびアルケニル修飾ベツリン酸誘導体 |
| WO2014160689A1 (en) * | 2013-03-27 | 2014-10-02 | Bristol-Myers Squibb Company | Piperazine and homopiperazine derivatives as hiv attachment inhibitors |
| PT2978763T (pt) * | 2013-03-27 | 2018-04-16 | Viiv Healthcare Uk No 5 Ltd | Derivados de 2-cetoamida como inibidores da ligação do vih |
| NZ724644A (en) | 2014-04-11 | 2023-07-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| WO2015195776A1 (en) | 2014-06-19 | 2015-12-23 | Bristol-Myers Squibb Company | Betulinic acid derivatives with hiv maturation inhibitory activity |
| EP3218387A1 (en) | 2014-11-14 | 2017-09-20 | VIIV Healthcare UK (No.5) Limited | Oxolupene derivatives |
| BR112017009852A2 (pt) | 2014-11-14 | 2018-01-16 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, usos de um composto |
| CA2971096A1 (en) | 2014-12-18 | 2016-06-23 | ViiV Healthcare UK (No.4) Limited | A process for preparing halogenated azaindole compounds using pybrop |
| JP6554542B2 (ja) | 2014-12-18 | 2019-07-31 | ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド | ボロキシンを使用してハロゲン化アザインドール化合物を調製するための方法 |
| CN107428798A (zh) | 2015-04-14 | 2017-12-01 | Viiv保健英国第四有限公司 | 生产hiv成熟抑制剂的方法 |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| CN108473516B (zh) * | 2015-12-14 | 2021-06-18 | 马克斯·普朗克科学促进协会 | 3,5-二苯基-二唑化合物的水溶性衍生物 |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3411033A1 (en) | 2016-02-04 | 2018-12-12 | ViiV Healthcare UK (No.5) Limited | Fostemsavir for use in heavily treatment-experienced hiv-1 infected individuals |
| BR122023021456A2 (pt) | 2016-02-26 | 2024-02-20 | Debiopharm International S.A. | Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica |
| IL313710A (en) | 2017-11-21 | 2024-08-01 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| EP3911651B1 (en) | 2019-01-17 | 2024-01-10 | ViiV Healthcare UK (No.4) Limited | Process for preparing fostemsavir |
| FI3923914T3 (fi) | 2019-02-14 | 2023-04-27 | Debiopharm Int Sa | Afabisiiniformulaatio, menetelmä sen valmistamiseksi |
| MA56184A (fr) | 2019-06-14 | 2022-04-20 | Debiopharm Int Sa | Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| US20240425568A1 (en) | 2021-12-17 | 2024-12-26 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
| UY40507A (es) | 2022-11-02 | 2024-04-30 | Viiv Healthcare Uk No 5 Ltd | Proteínas de unión a antígeno |
| WO2025229018A1 (en) | 2024-04-30 | 2025-11-06 | VIIV Healthcare UK (No.5) Limited | Neutralizing antibody constructs against hiv |
| TW202607015A (zh) | 2024-04-30 | 2026-02-16 | 英商Viiv醫療保健英國(No 5)有限公司 | 抗原結合蛋白 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5619238A (en) | 1992-07-24 | 1997-04-08 | Canon Kabushiki Kaisha | Method of making replaceable ink cartridge |
| US6469006B1 (en) * | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
| US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| WO2002004440A1 (en) * | 2000-07-10 | 2002-01-17 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| RU2303038C2 (ru) * | 2001-02-02 | 2007-07-20 | Бристол-Маерс Сквибб Компани | Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| WO2003082881A2 (en) | 2002-03-28 | 2003-10-09 | Procyon Biopharma Inc. | Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors |
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US7776863B2 (en) | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
| US7130185B2 (en) * | 2004-06-02 | 2006-10-31 | Research In Motion Limited | Handheld computing device having drop-resistant LCD display |
| US7723338B2 (en) * | 2005-01-31 | 2010-05-25 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| CN103339130B (zh) * | 2011-01-31 | 2015-05-06 | 百时美施贵宝公司 | 制备hiv附着抑制剂前药化合物的方法及中间体 |
| MX352320B (es) * | 2012-02-08 | 2017-11-21 | Viiv Healthcare Uk No 4 Ltd | Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana. |
-
2005
- 2005-02-25 US US11/066,745 patent/US7745625B2/en active Active
- 2005-03-03 EP EP05724510A patent/EP1725569B1/en not_active Expired - Lifetime
- 2005-03-03 WO PCT/US2005/006980 patent/WO2005090367A1/en not_active Ceased
- 2005-03-03 ES ES05724510T patent/ES2299022T3/es not_active Expired - Lifetime
- 2005-03-03 DK DK05724510T patent/DK1725569T3/da active
- 2005-03-03 AT AT05724510T patent/ATE384728T1/de active
- 2005-03-03 KR KR1020067021381A patent/KR101153594B1/ko not_active Expired - Lifetime
- 2005-03-03 JP JP2007503935A patent/JP4734318B2/ja not_active Expired - Lifetime
- 2005-03-03 NZ NZ585294A patent/NZ585294A/en not_active IP Right Cessation
- 2005-03-03 CA CA2560253A patent/CA2560253C/en not_active Expired - Lifetime
- 2005-03-03 BR BRPI0508876A patent/BRPI0508876B8/pt not_active IP Right Cessation
- 2005-03-03 PT PT05724510T patent/PT1725569E/pt unknown
- 2005-03-03 GE GEAP20059660A patent/GEP20094736B/en unknown
- 2005-03-03 AU AU2005223736A patent/AU2005223736C1/en active Active
- 2005-03-03 RS RSP-2008/0060A patent/RS50567B/sr unknown
- 2005-03-03 CN CN2010101669503A patent/CN101941990B/zh not_active Expired - Lifetime
- 2005-03-03 NZ NZ549867A patent/NZ549867A/en not_active IP Right Cessation
- 2005-03-03 PL PL05724510T patent/PL1725569T3/pl unknown
- 2005-03-03 HR HR20080064T patent/HRP20080064T5/xx unknown
- 2005-03-03 DE DE602005004517T patent/DE602005004517T2/de not_active Expired - Lifetime
- 2005-03-09 TW TW094107202A patent/TWI344843B/zh active
- 2005-03-12 MY MYPI20051051A patent/MY139243A/en unknown
- 2005-03-15 PE PE2005000289A patent/PE20051151A1/es active IP Right Grant
- 2005-03-15 AR ARP050100996A patent/AR048039A1/es active IP Right Grant
-
2006
- 2006-09-08 NO NO20064062A patent/NO336742B1/no unknown
-
2008
- 2008-04-21 CY CY20081100447T patent/CY1107419T1/el unknown
-
2010
- 2010-04-26 US US12/767,222 patent/US8168615B2/en active Active
-
2011
- 2011-03-27 IL IL211961A patent/IL211961A/en active IP Right Grant
-
2012
- 2012-03-26 US US13/429,838 patent/US8461333B2/en not_active Expired - Lifetime
-
2013
- 2013-04-12 US US13/861,804 patent/US8871771B2/en not_active Expired - Lifetime
-
2014
- 2014-04-10 US US14/249,638 patent/US20150025240A1/en not_active Abandoned
-
2015
- 2015-05-05 US US14/704,183 patent/US20150232414A1/en not_active Abandoned
- 2015-07-15 US US14/800,315 patent/US20150315218A1/en not_active Abandoned
-
2016
- 2016-08-29 US US15/249,827 patent/US20160361328A1/en not_active Abandoned
-
2017
- 2017-09-14 US US15/704,100 patent/US20180000849A1/en not_active Abandoned
-
2018
- 2018-11-14 US US16/190,632 patent/US20190111066A1/en not_active Abandoned
-
2019
- 2019-10-22 US US16/659,786 patent/US20200046743A1/en not_active Abandoned
-
2020
- 2020-10-13 US US17/068,902 patent/US11369624B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1725569E (pt) | Pró-fármacos de piperazina e agentes antivirais de piperidina substituída | |
| IL194540A (en) | Dicto-piperazine and piperidine derivatives used as antiviral agents | |
| AP2006003768A0 (en) | TetraazabenzoÄeÜazulene derivatives and analogs tehereof | |
| IL186804A0 (en) | A combination of a pde4 inhibitor and a tetrahydrobiopterin derivative | |
| SI1802579T1 (sl) | Derivati 3-arilaminopiridina | |
| IL211894A0 (en) | Amide derivatives | |
| PL1648874T3 (pl) | Pochodne piperazyny i ich zastosowanie jako środków leczniczych | |
| IL181433A0 (en) | Pyrimidine derivatives | |
| IL181609A0 (en) | Combination comprising zd6474 and imatinib | |
| IL183216A0 (en) | Nepetalactams and n-substituted derivatives thereof | |
| IL181386A0 (en) | Pyrimidine derivatives | |
| GB0415364D0 (en) | Pyrimidine derivatives | |
| IL183293A0 (en) | Malonamide derivatives | |
| IL183217A0 (en) | Dihydronepetalactams and n-substituted derivatives thereof | |
| GB0415367D0 (en) | Pyrimidine derivatives | |
| IL179914A0 (en) | Pyrimidine derivatives | |
| IL176922A0 (en) | Compositions and methods of use of a-type procyanidins | |
| IL176426A0 (en) | Di-steroidal prodrugs of estradiol | |
| IL178888A0 (en) | Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives | |
| ZA200607466B (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
| ZA200808819B (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| IL177945A0 (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
| SI1725569T1 (sl) | Predzdravila piperazinskih in substituiranih piperidinskih protivirusnih sredstev | |
| ZA200702227B (en) | Combination comprising ZD6474 and imatinib | |
| ZA200705150B (en) | Amide derivatives |